Drug intelligence / Profile preview

SygeLIX-G

Development stage: Phase 1
Lead developer: TBF Génie Tissulaire
Modality: Cell Therapies
Administration: Local Application

Overview

SygeLIX-G is a gel composed of Wharton's jelly, a gelatinous substance found in the umbilical cord that is rich in mesenchymal stem cells. It is being investigated for the treatment of ano-perineal fistulas that are resistant to surgical intervention. The gel is designed to be applied locally to fill the cryptoglandular space, working in conjunction with a SygeLIX-F plug. Its therapeutic action is believed to stem from the regenerative, immunomodulatory, and anti-inflammatory properties inherent in Wharton's jelly.

Beyond the preview

Go deeper on SygeLIX-G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SygeLIX-G.

Explore the full profile